Neha N. Parayath

Neha N. Parayath

Auto-generated profile, based on publicly available information

Neha N. Parayath

Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

12 September 2019 in Nanoscale
Verified
Journal Article
Closed access
PDF file
DCDongyu Chen
Dongyu Chen
NPNeha Parayath
Neha Parayath
SGShanthi Ganesh
Shanthi Ganesh
WWWeimin Wang
Weimin Wang
Mansoor M. AmijiMansoor M. Amiji
Mansoor M. Amiji
The application of lipid-based nanoparticle (LNP) delivery systems remains a popular strategy for the systemic delivery of gene therapies to specific disease targets, including solid tumors. It is now well acknowledged that upon systemic administration, biomolecules from blood will adsorb onto nanoparticles’ surfaces, forming a “protein corona”, affording nanoparticles a “biological identity” on top of their “synthetic identity”. Detailed analysis of nanoparticle protein corona is gradually revealing the “missing link” between nanoparticle chemical properties and the biological identity. Nevertheless, the discovery of nanoparticle protein corona's impact on tumor delivery is limited. In this study, we demonstrate that protein corona can be manipulated by formulation composition and particle surface charge changes, and a single lipid switch could switch the nanoparticle protein corona profile. The protein corona composition differences had a profound impact on cell transfection, in vivo biodistribution as well as tumor-specific delivery efficiency. Nanoparticles with apolipoprotein-rich corona showed better delivery to hepatocellular carcinoma (HepG2) as compared to those with vitronectin-rich corona. In addition, we found that, the PEG conjugated lipid chain length and PEG amount in LNPs were key factors to consider in successful RNA interference therapy for solid tumors.

1 May 2014 in International Journal of Nanomedicine
Verified
Journal Article
Open access
Khaled GreishKhaled Greish
Khaled Greish
HNHayley Nehoff
Hayley Nehoff
NPNeha N Parayath
Neha N Parayath
LDLaura Domanovitch
Laura Domanovitch
STSebastien Taurin
Sebastien Taurin
The growing research interest in nanomedicine for the treatment of cancer and inflammatory-related pathologies is yielding encouraging results. Unfortunately, enthusiasm is tempered by the limited specificity of the enhanced permeability and retention effect. Factors such as lack of cellular specificity, low vascular density, and early release of active agents prior to reaching their target contribute to the limitations of the enhanced permeability and retention effect. However, improved nanomedicine designs are creating opportunities to overcome these problems. In this review, we present examples of the advances made in this field and endeavor to highlight the potential of these emerging technologies to improve targeting of nanomedicine to specific pathological cells and tissues.

1 October 2019 in Cancer Letters
Verified
Journal Article
Closed access
NPNeha N. Parayath
Neha N. Parayath
SGSrujan Kumar Gandham
Srujan Kumar Gandham
FLFraser Leslie
Fraser Leslie
Mansoor M. AmijiMansoor M. Amiji
Mansoor M. Amiji


1 October 2014 in Therapeutic Delivery
Verified
Journal Article
Closed access
SMSalma Mohamed
Salma Mohamed
NPNeha N Parayath
Neha N Parayath
STSebastien Taurin
Sebastien Taurin
Khaled GreishKhaled Greish
Khaled Greish
Polymeric micelles are among the most promising delivery systems in nanomedicine. The growing interest in polymeric micelles as drug delivery vehicle is promoted by the advantages they offer for hydrophobic anticancer agents. The size of most polymeric micelles lies within the range 10-100 nm ensuring that they can selectively leave the circulation at tumor site via the enhanced permeability and retention effect. Their unique structure allows them to solubilize hydrophobic drugs, prolongs their circulatory half-life and eventually leads to enhanced therapeutic efficacy. In addition, they can undergo several structural modifications to further augment tumor cell uptake. In this review, we will discuss various micellar systems that have been studied in preclinical and clinical settings.